Streetbeat News

AGNPF

Algernon Pharmaceuticals Inc

https://algernonpharmaceuticals.com

Industry

Pharmaceutical Preparation Manufacturing

Open

0.06

Mkt cap

1.7M

Volume

7.4K

High

0.06

P/E Ratio

-6.28

52-wk high

0.12

Low

0.06

Div yield

N/A

52-wk low

0.04

Algernon Pharmaceuticals Inc. has appointed Dr. Sándor Nardai as the Principal Investigator for its upcoming Phase 2a DMT study on stroke patients, set to begin in Q3 2025.

Portfolio Pulse from

February 11, 2025 | 12:15 pm

Algernon Pharmaceuticals' subsidiary, Algernon NeuroScience, has appointed Validcare as the CRO for its Phase 2a DMT stroke trial. Validcare also made a $170K equity investment in Algernon. The trial will involve 40 stroke patients in Europe and is set to start in Q3 2025.

Portfolio Pulse from

February 05, 2025 | 12:15 pm

Algernon Pharmaceuticals has announced an extension of its warrants. This decision is not intended for distribution to U.S. newswire services.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

The American Psychedelic Practitioners Association and BrainFutures have published the first-ever professional practice guidelines for psychedelic-assisted therapy. Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has finalized its clinical trial design for a phase 2 DMT stroke study. Atai Life Sciences, MindMed, and COMPASS Pathways have reported their Q2 2023 financial results. AdvisorShares Psychedelics ETF has seen a decrease in its weekly performance.

Portfolio Pulse from Lara Goldstein

August 14, 2023 | 1:47 pm

Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals Inc., has completed a feasibility study and finalized its clinical trial design for a phase 2 DMT stroke study. The trial will study an intravenous sub-psychedelic dose of DMT in patients who have suffered an acute ischemic stroke. The decision to investigate DMT for stroke treatment was based on a 2020-published rat occlusion stroke study showing that DMT reduced infarct volume and led to almost full recovery of motor function. The company plans to conduct the study at multiple locations in Europe.

Portfolio Pulse from Vuk Zdinjak

August 08, 2023 | 3:00 pm

Algernon Pharmaceuticals' subsidiary, Algernon NeuroScience, has completed dosing the final cohort of its Phase 1 clinical study for its DMT compound, AP-188, aimed at treating stroke and Traumatic Brain Injury (TBI). The study found no safety or tolerability issues, and the company plans to accelerate its Phase 2 studies for both stroke and TBI.

Portfolio Pulse from Lara Goldstein

June 05, 2023 | 5:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.